Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Binge Eating Disorder - Overview
Binge Eating Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Binge Eating Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Binge Eating Disorder - Companies Involved in Therapeutics Development
Amygdala Neurosciences Inc
Bright Minds Biosciences Inc
Chronos Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Idorsia Pharmaceutical Ltd
Omeros Corp
OXonium Therapeutics
Seropeutics LLC
Vivus Inc
Yichang Renfu Pharmaceutical Co Ltd
Binge Eating Disorder - Drug Profiles
(phentermine hydrochloride + topiramate) ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-539313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANS-6637 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-010018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lisdexamphetamine dimesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize 5 HT2C for Neurology and Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Binge Eating Disorder - Dormant Projects
Binge Eating Disorder - Discontinued Products
Binge Eating Disorder - Product Development Milestones
Featured News & Press Releases
Mar 03, 2021: Bright Minds Biosciences (“BMB”) proprietary 5-HT2C agonists show significant reduction in binge eating
May 02, 2018: Chronos Therapeutics announces positive pre-clinical proof of concept studies for its Orexin-1 antagonist project initially targeting binge eating disorder
Oct 06, 2016: Study Finds New Approach to Block Binge Eating
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Binge Eating Disorder, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Binge Eating Disorder, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Binge Eating Disorder - Pipeline by Amygdala Neurosciences Inc, 2021
Binge Eating Disorder - Pipeline by Bright Minds Biosciences Inc, 2021
Binge Eating Disorder - Pipeline by Chronos Therapeutics Ltd, 2021
Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Binge Eating Disorder - Pipeline by Idorsia Pharmaceutical Ltd, 2021
Binge Eating Disorder - Pipeline by Omeros Corp, 2021
Binge Eating Disorder - Pipeline by OXonium Therapeutics, 2021
Binge Eating Disorder - Pipeline by Seropeutics LLC, 2021
Binge Eating Disorder - Pipeline by Vivus Inc, 2021
Binge Eating Disorder - Pipeline by Yichang Renfu Pharmaceutical Co Ltd, 2021
Binge Eating Disorder - Dormant Projects, 2021
Binge Eating Disorder - Discontinued Products, 2021